Fumaric Acid

Fumaric Acid

SCHEMBL4483583

CC(C)N(Cc1cccc(Cl)c1)[C@H]1CCNC1.O=C(O)/C=C/C(=O)O

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol

The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
SLC6A2 known ✓ P23975 14/20 0.54
SLC6A4 known ✓ P31645 13/20 0.54
KCNH2 known ✓ Q12809 2/20 0.47
SLC6A3 Q01959 8/20 0.54
MBTPS1 Q14703 2/20 0.50
TACR1 P25103 3/20 0.49
CYP2D6 P10635 2/20 0.47
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL4483585 1.00 SLC6A2 (0.54) SLC6A2SLC6A4SLC6A3MBTPS1TACR1
SCHEMBL4484165 0.90 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3MBTPS1TACR1
Fumaric Acid SCHEMBL4481895 0.89 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
Fumaric Acid SCHEMBL4481893 0.89 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
Fumaric Acid SCHEMBL4491779 0.88 SLC6A2 (0.54) SLC6A2SLC6A4SLC6A3MBTPS1CYP2D6
Fumaric Acid SCHEMBL4491783 0.88 SLC6A2 (0.54) SLC6A2SLC6A4SLC6A3MBTPS1CYP2D6
Fumaric Acid SCHEMBL4693202 0.86 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
Fumaric Acid SCHEMBL4491704 0.86 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
Fumaric Acid SCHEMBL4485551 0.85 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3KCNH2
Fumaric Acid SCHEMBL4493089 0.85 SLC6A2 (0.71) SLC6A2SLC6A4SLC6A3TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7619096-B2 3-Aminopyrrolidines as inhibitors of monoamine uptake ELI LILLY AND COMPANY (US) 2009-11-17 US disclosed
EP-1638934-B1 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE LILLY CO ELI (US) 2008-01-09 EP disclosed
US-20060270713-A1 3-Aminopyrrolidines as inhibitors of monoamine uptake ELI LILLY AND COMPANY 2006-11-30 US disclosed
EP-1638934-A1 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE ELI LILLY AND COMPANY (US) 2006-03-29 EP disclosed
WO-2005000811-A1 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE ELI LILLY AND COMPANY (US) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270713-A1 3-Aminopyrrolidines as inhibitors of monoamine uptake SLC6A2, SLC6A3, SLC18A2 SLC6A2 1/4885SLC6A4 5/4885KCNH2 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.